Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
AssigneeNovartis AG
InventorsHolger Petersen, Markus Ahlheim
Life of this patent
Estimating the term…
Abstract
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-coglycolide polymers (PLGAs).
Claims19
A sustained release pharmaceutical composition in form of microparticles comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different polylactide-co-glycolide polymers (PLGAs), wherein the PLGAs are present as polymer blend, and wherein the microparticles are of a single composition and wherein the lactide:
- glycolide ratios of the different PLGAs are different from each other.
A sustained release pharmaceutical composition in form of microparticles comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different polylactide-co-glycolide polymers (PLGAs), wherein the lactide:
- glycolide ratios of the different PLGAs are different from each other, wherein the sustained release pharmaceutical composition is a mixture of depots, which is a mixture of two microparticles of different compositions, each with one different PLGA.
The sustained release pharmaceutical composition according to clai herein the PLGAs have a lactide:glycolide monomer ratio of 90:10 to 40:60.
Dependencies are inferred from the claim text.